FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium
TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
Blog - Melanoma360
05/25/2022
FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium
TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
|
05/25/2022
COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma
By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
|
05/25/2022
Part II In Plain English: When and How Melanoma Spreads to the Brain, and How it is Treated
By Kim Margolin, M.D., FACP, FASCO Background about melanoma and other malignancies involving the brain Of all the kinds of…
|
05/25/2022
Part I In Plain English—When, How, and Where Melanoma Spreads
By Kim Margolin, M.D., FACP, FASCO The vast majority of people diagnosed with cutaneous melanoma are cured by one or…
|
05/24/2022
Being Your Own Advocate
In today’s busy medical practices, you need to be involved in your own care (or that of a loved one)…
|
05/24/2022
International Advocate Spotlight: Claudia Piazza Cidonio
by Mara Klecker Most of Claudia Piazza Cidonio’s family studied medicine and went on to become doctors – something she…
|
|
04/19/2022
Shannon Eberly, Stage IV Melanoma Survivor- Sharing is Everything
By Mara Klecker Shannon Eberly is fair-skinned and freckled, but she never had a mole on her skin that looked…
|
04/12/2022
Drawing Strength From Music
Music can play a powerful role in helping patients find strength and comfort both during and after treatment. In this…
|
03/21/2022
Life After Loss: Lisa Huntley’s Life Has Come Full Circle
by Mara Klecker Lisa Huntley remembers walking out of the hospital without her husband, Grant, in 1994 and thinking to…
|
|
03/19/2022
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
|
Recent Posts
May. 01, 2025
AIM at Melanoma + WEARSPF®: Partnering for a Cause This Melanoma Awareness Month
May. 01, 2025
Hope, Purpose, and Progress: Melanoma Awareness Month with AIM
Apr. 28, 2025
Your Style Can Save Lives – Lilly Pulitzer Giving Day is Here!
Apr. 28, 2025
From Diagnosis to Crown: Miss Pennsylvania’s Journey of Advocacy and Awareness
Apr. 24, 2025